EYKON Strengthens Strategic Focus Through Sale of Water Meter Business to Sensus International

CHAM, Switzerland, Sept. 22, 2026 /PRNewswire/ -- EYKON and Sensus International, both part of the AURELIUS Midmarket portfolio, have entered into an agreement under which EYKON will sell its water meter business to Sensus International.

The agreement enables both organisations to focus on their respective strengths and supports EYKON's strategic focus in the areas where the company has established scale, long-standing customer relationships and leading positions across its portfolio.

Over recent years, EYKON has successfully established a presence in the water sector while continuing to build on its long-standing expertise in advanced metering, connectivity and digital utility solutions. This transaction marks the next step in EYKON's portfolio evolution and supports the company's continued investment in advanced metering, connectivity and digital utility solutions.

Following the transition, water metering business will continue under Sensus International, a dedicated water metering provider with a long-standing presence in the sector.

"For decades, utilities have trusted EYKON to support critical infrastructure through advanced metering, connectivity and digital utility solutions. We are committed to building on these strengths and helping customers improve operational performance, resilience and long-term value from their infrastructure investments," said Alexander Henschel, Chief Executive Officer of EYKON.

EYKON will continue to fulfil existing customer commitments in accordance with agreed terms. Continuity, quality and long-term reliability remain priorities throughout the transition.

Sensus International designs and delivers advanced water and thermal energy metering and infrastructure solutions for modern utilities. Its solutions combine deep metrology expertise with secure communications so that customers receive reliable performance, precise measurement and data they can stand behind.

Sensus International employs more than 800 people across Europe, the Middle East, Latin America, and Asia, reflecting its strong international presence.

More information: www.sensus-international.com

EYKON, formerly the Landis+Gyr EMEA business, operates as an independent utility infrastructure technology company built on more than 130 years of utility expertise. Headquartered in Switzerland, with a network of expert local teams, the company serves customers in more than 75 markets and supports over 100 million connected endpoints across the region.

Combining proven technology, deep utility expertise and real-world operational insight from one of the largest installed bases in EMEA, EYKON connects what utilities measure with how they operate. This helps customers gain greater visibility, make better decisions, maintain greater control and unlock more value from their infrastructure.

More information: eykon-solutions.com

About AURELIUS

AURELIUS is a global private equity investor, distinguished and widely recognised for its operational approach. It focuses on private markets, in particular Private Equity and Private Debt. Its key investment platforms include AURELIUS Opportunities V, AURELIUS European Opportunities IV, AUR Portfolio III and AURELIUS Growth. AURELIUS has been growing significantly in recent years, especially expanding its global footprint, and today employs more than 400 professionals in ten offices spanning Europe, North America and Asia.

AURELIUS is a renowned specialist for complex investments with operational improvement potential such as carve-outs, platform build-ups or succession solutions as well as bespoke financing solutions. To date, AURELIUS has completed more than 300 transactions and has built a strong track record of delivering attractive returns to its investors. Its approach is characterised by its uncompromising focus on operational excellence and an unrivalled ability to efficiently execute highly complex transactions.

More info: www.aurelius-group.com

Share this article

Nice expands its European critical infrastructure security capabilities with its HySecurity division

The Nice group formalizes its entry into the European hostile vehicle mitigation market with CE-certified products from its HySecurity division, on show at International Security Expo 2026

LONDON, Sept. 22, 2026 /PRNewswire/ -- Nice, an international technology group specializing in Smart Living solutions, is strengthening its presence in the European security market with the structured introduction of its HySecurity division, offering high-security gates, barriers and hostile vehicle mitigation (HVM) solutions.

The solutions will be presented at International Security Expo 2026, taking place at Olympia London on 29-30 September, where Nice will exhibit at Booth C90.

HySecurity, part of the Nice group since 2016, brings more than 60 years of expertise in hydraulic gate operators and crash-rated barriers for high-security and critical-infrastructure sites, such as airports, government facilities and data centres. Its promise puts people at the center: protecting people and places to keep the world moving.

Until now, HySecurity products have reached European specifiers primarily on a project-by-project basis. Following CE certification of an initial product range, Nice is establishing a structured route to market in Europe, supported by local commercial and technical teams and the Group's network of installers and system integrators. Nice is well known in the European panorama, and it exists so people can move through their everyday lives freely, safely, and without a second thought — this is the promise of Smart Living. HySecurity extends that same promise to the places society depends on most: airports, borders, data centers, government sites.

This expansion comes as physical infrastructure protection rises on the European agenda. Transport hubs, energy and water networks, data centres, government sites, logistics facilities and public spaces share the same challenge: strengthening protection without obstructing people, vehicles or operations.

Regulation reflects this shift. The European Commission's proposed Public Procurement Act emphasizes resilience and security of supply in strategic sectors, while CER and NIS2 have reinforced infrastructure resilience across Europe. In the UK, data centres are now designated Critical National Infrastructure and are being brought under a stronger statutory resilience framework.

The result is growing demand for systems that combine physical protection, controlled access and operational reliability, which is exactly what Nice aims to deliver through its HySecurity division.

High-security solutions for the European market

At ISE, Nice will showcase three CE-certified solutions now available in Europe:

- StrongArm® M30/M50 crash-rated HVM barrier arm;

- SlideDriver™ II hydraulic slide gate operator;

- HydraSwing® heavy-duty hydraulic swing gate operator.

All three solutions integrate with Nice's access, control and connectivity ecosystem, enabling high-security access points to operate as part of a wider site management environment.

Nice will also present solutions from its established automation portfolio, including the Titan 6024HS high-speed swing gate operator with MC824H control unit, the M5 Bar road barrier and the Tub4000 underground operator.

More information: https://www.niceforyou.com/en/internationalsecurityexpo

About Nice: www.niceforyou.com

SOURCE Nice

Share this article

NUH's Inpatient DM management team highlights how safe prescribing is strengthened through proactive monitoring, rapid intervention and coordinated care transitions.

SINGAPORE, Sept. 21, 2026 /PRNewswire/ -- Newer diabetes treatments are transforming care, helping patients not only manage their blood sugar levels but also protect their hearts and kidneys while reducing the risk of serious complications. However, unlocking the full benefits of these medications requires more than prescribing the right drug. Safe use depends on timely monitoring, patient education and coordinated care across every stage of treatment.

Recognising this, the NUH DM team has developed a multidisciplinary care model that supports patients from the point of prescribing through hospitalisation, discharge and recovery in the community. Bringing together physicians, nurses, pharmacists and care coordinators, the approach strengthens medication safety while helping patients benefit from the latest advances in diabetes care.

The team's initiatives were showcased at the NICQ-NUH Grand Rounds: Safe Prescribing, Safe Transitions, Safe Recovery at NUHS, a multidisciplinary educational forum for healthcare professionals held in conjunction with World Patient Safety Day 2026. Centred on the theme of non-communicable diseases (NCDs), the theme for this year's World Patient Safety Day "Self Care for Life" emphasises safe care for NCDs cannot rest on healthcare professionals alone. It requires patients, families, and communities to be active, informed partners in that care journey. The DM team's initiative tackles a critical paradox that many of us in clinical practice will recognise: in diabetes care, both action and inaction carry risk.

Led by Adjunct Associate Professor Khoo Chin Meng from the Division of Endocrinology, Department of Medicine, NUH, the session highlighted a number of initiatives implemented at NUH. These include SPARK, a proactive digital monitoring programme that identifies hospitalised patients at risk of hyperglycaemia before complications occur; HypoBox, a nurse-led intervention that enables the rapid treatment of hypoglycaemia; and structured care-transition processes that support patients beyond discharge.

Advancing safe prescribing in modern diabetes care

For the NUH DM team, safe prescribing does not end when a medication is prescribed. It extends across every stage of a patient's journey, from treatment initiation and inpatient care to discharge and recovery in the community.

This philosophy underpins a coordinated care model that combines patient education, proactive monitoring and multidisciplinary support to help prevent, identify and manage treatment-related complications.

Adj A/Prof Khoo Chin Meng, Division of Endocrinology, Department of Medicine NUH, said:

"The evidence is clear that SGLT2 inhibitors and GLP-1 receptor agonists improve outcomes for patients with diabetes by protecting the heart and kidneys and reducing the risk of serious complications. As clinicians, we have a responsibility to ensure that patients receive these therapies when appropriate. Equally important, however, is ensuring that patients, caregivers and healthcare professionals are equipped to recognise and manage potential adverse effects. Safe prescribing is not simply about selecting the right medication. It is about building the systems, education and support structures that allow patients to use these treatments safely across every stage of care."

Proactively identifying at-risk patients through SPARK

Most hospital systems respond when a problem is detected. SPARK was designed to do the opposite.

A cornerstone of NUH's inpatient diabetes safety framework, the digital programme enables the DM team to identify patients at risk of poor glycaemic control before complications occur. Rather than waiting for an alert, referral or clinical deterioration, clinicians proactively seek out patients who may require specialist support, allowing intervention at an earlier stage.

Integrated within NUH's electronic medical record system, SPARK continuously screens inpatient data and generates lists of patients who may be at risk of poor glycaemic control. Using SPARK, we developed the ProActive Service (since 2018) to identify those patients with DM who will be reviewed earlier by the Inpatient DM management team as their first touchpoint of care.

The ProActive Service currently includes the following groups of patients:

- For patients with DM admitted with hyperglycemic crisis (Diabetic Ketoacidosis or Hyperosmolar Hyperglycaemic State) or severe hypoglycaemia.

- For patients with DM who have undergone Coronary Artery Bypass Grafting surgery

- Patients with DM in all Surgical wards and Cardiology who have hyperglycaemia[1] and/or hypoglycaemia[2]

What distinguishes SPARK is its focus on identifying patients before they experience preventable complications. By proactively reviewing patients across the hospital, the team is able to optimise glucose control earlier, support wound healing, reduce the risk of infection and other diabetes-related complications, and facilitate recovery during hospitalisation.

Today, SPARK is supported by a multidisciplinary team comprising physicians, nurses and pharmacists who work alongside primary teams to optimise inpatient DM management.

Dr Doddabele Srinivasa Deepak, Senior Consultant, Division of Endocrinology, Department of Medicine, NUH, said:

"SPARK was developed on the principle that we should not wait for patients to become unwell before intervening. By proactively identifying patients at risk, we can initiate appropriate management earlier, support primary teams and reduce the likelihood of avoidable complications. This allows us to deliver safer and more coordinated care across the hospital."

Empowering nurses to respond rapidly to Hypoglycaemia

Complementing SPARK is HypoBox, an initiative developed by the nurses within the NUH DM team to enable the rapid management of hypoglycaemia. HypoBox is a nurse-led initiative designed to enable rapid and standardised treatment of hypoglycaemic emergencies. By bringing essential treatment supplies and the management protocol together at the point of care, nurses can intervene promptly, confidently and consistently. Located in wards and clinics across NUH, the ready-to-use emergency kit that contains fast-acting glucose, complex carbohydrate options and hypoglycaemia management guidelines.

Hypoglycaemia remains one of the most common complications encountered by hospitalised patients receiving glucose-lowering treatment. If not recognised and treated promptly, severe episodes can result in seizures, loss of consciousness, neurological injury, coma and other serious adverse outcomes.

Since its implementation, more patients are able to achieve hypoglycaemia rescue within the recommended target time, enabling earlier recovery and reducing the risk of progression to severe hypoglycaemia. This reduces variability in practice and enhances patient safety.

Ms Heng Boon Ling, Advanced Practice Nurse, Nursing Department, NUH, who spearheaded the initiative, said:

"HypoBox began as a ground-up effort to make hypoglycaemia treatment faster, simpler and more consistent for frontline staff. During a hypoglycaemic event, every minute matters. We wanted nurses to have immediate access to the right treatment and clear instructions so they could act without delay. Through the train-the-trainer approach, we have built capability across the organisation and strengthened confidence in delivering safe diabetes care."

Together, the NUH DM team's safe prescribing framework, SPARK digital programme, HypoBox initiative and structured transition-of-care processes form an integrated safety ecosystem that supports patients throughout the continuum of diabetes care.

Delivered by a multidisciplinary team of physicians, Advanced Practice Nurses, pharmacists and care coordinators, the model demonstrates how healthcare systems can maximise the benefits of life-saving diabetes therapies while ensuring that robust safeguards are in place to prevent avoidable harm.

About the National University Hospital (NUH)

The National University Hospital (NUH) is Singapore's leading university hospital. While the hospital at Kent Ridge first received its patients on 24 June 1985, our legacy started from 1905, the date of the founding of what is today the NUS Yong Loo Lin School of Medicine. NUH is the principal teaching hospital of the medical school.

Our unique identity as a university hospital is a key attraction for healthcare professionals who aspire to do more than practise tertiary medical care. We offer an environment where research and teaching are an integral part of medicine, and continue to shape medicine and transform care for the community we care for.

We are an academic medical centre with over 1,200 beds, serving more than one million patients a year with over 50 medical, surgical and dental specialties. NUH is the only public and not-for-profit hospital in Singapore to provide trusted care for adults, women and children under one roof, including the only paediatric kidney and liver transplant programme in the country.

The NUH is a key member of the National University Health System (NUHS), one of three public healthcare clusters in Singapore. For more information, visit www.nuh.com.sg

SOURCE National University Hospital (NUH)

Share this article

Travelers can save up to 60% on resorts and enjoy exclusive deals on dining, entertainment and more Sept. 22–26

Book Offers Now at VisitLasVegas.com/5DaySale

LAS VEGAS, Sept. 22, 2026 /PRNewswire/ -- Consider this your official sign to stop staring at the calendar and start planning the escape. Routines can wait. Vegas cannot.

The "Vegas 5-Day Sale" is back, bringing more than 180 limited-time offers starting today, Tuesday, Sept. 22, through Saturday, Sept. 26. Travelers can score savings of up to 60% on resort stays, along with deals on world-class dining, headline entertainment, attractions, nightlife, wedding packages and more.

"Vegas is where travelers come to trade the expected for the unforgettable," said Kate Wik, Chief Marketing Officer at the Las Vegas Convention and Visitors Authority, "The 'Vegas 5-Day Sale' gives visitors even more reasons to book the trip they have been talking about, whether that means checking into an iconic resort, seeing a favorite artist live, celebrating a milestone or simply making a little room for spontaneity."

With offers available across the Strip, downtown and beyond, the sale invites visitors to build a getaway their way: high-roller luxury, pampered relaxation, culinary indulgence, late-night adventure or all the above.

Resort Offers Across Las Vegas

- Boyd Gaming:

- $200 Package with promo code PWINT at Aliante Casino + Hotel + Spa, Suncoast Hotel & Casino, and The Orleans Hotel & Casino. $150 Packages at Cannery Casino Hotel, Gold Coast Hotel & Casino, and Sam's Town Hotel & Gambling Hall. And $100 packages at California Hotel & Casino, Fremont Hotel & Casino, and Main Street Station Casino Brewery Hotel.

- Caesars Entertainment:

- Up to 60% off room rates and $50 F&B credit at Flamingo Las Vegas, Harrah's Las Vegas, Horseshoe Las Vegas, and The LINQ.

- Up to 55% off room rates at Planet Hollywood Resort & Casino.

- Up to 30% off room rates at Nobu Hotel Caesars Palace.

- Up to 30% off at Caesars Palace and Paris Las Vegas, and up to 35% off at Vanderpump Hotel, each with daily breakfast included.

- Circa Hospitality:

- The D Las Vegas and Golden Gate Hotel & Casino: Two-night, $200 all-in package that includes $100 dining packages, admission to Stadium Swim, and is inclusive of resort fee and tax.

- Circa Resort & Casino: $400 all-in offer that includes $100 in dining credits, $100 in beverage credits, and a complimentary daybed at Stadium Swim.

- Ellis Island Hotel, Casino & Brewery: Up to 35% off when booking directly.

- Fontainebleau Las Vegas: Up to 20% off room rates, in addition to a $50 daily resort credit and free parking.

- Four Seasons Hotel Las Vegas: "Vegas Escape" up to 20% off room rates.

- Hilton Vacations Club: Vegas Winter Deal will offer 25% on select stays from at participating properties, including Hilton Grand Vacations Club on the Las Vegas Strip, Hilton Grand Vacations Club Paradise Las Vegas, Hilton Grand Vacations Club Elara Center Strip Las Vegas and more.

- MGM Resorts International:

- 50% off room rates at MGM Grand, Mandalay Bay, W Las Vegas, Park MGM, New York-New York Hotel & Casino, Luxor, Excalibur and more.

- 25% off room rates with a $100 daily food and beverage credit at ARIA, Bellagio, The Cosmopolitan of Las Vegas, and Vdara.

- Palms Casino Resort: 50% off room rates and 50% off resort fees.

- Plaza Hotel & Casino: The "Viva Package" will offer 25% off room rates, a $25 dining credit, and a bingo blue pack and dauber, in addition to free parking.

- Resorts World: $75 dining credit with stays that can be redeemed with curated menus across participating venues inside the Resort.

- SAHARA Las Vegas: Up to 60% off stays and complimentary late checkout until noon.

- Silverton Casino Lodge: 30% or more off room rates for two or more nights, in addition to $40 food and beverage credit, free late check out and free upgrade to pool view rooms.

- South Point: 10% off prevailing rates in addition to a discounted resort fee, in addition to $25 in free slot play and upgraded view rooms.

- Stations Casinos: Special room rates up to 30% off at Durango Casino and Resort, Red Rock Casino, Resort & Spa, Green Valley Ranch, Santa Fe Station and more.

- The STRAT Hotel, Casino & Tower: "Fall All-In Hotel Package" includes discounted room rates plus $50 resort credit per stay. Rates start at $49 midweek and $99 on weekends, with no resort fee or tax.

- Treasure Island: Deluxe room rates starting at $69 plus tax, with optional resort fee, in addition to 2-for-1 draft beers and always free parking.

- The Venetian and The Palazzo Resorts Las Vegas: 33% off two-night stays.

- Virgin Hotels Las Vegas: Up to 35% off room rates and a $25 food and beverage credit.

- Westgate Resort & Casino: Two-night, $199 all-inclusive package that will include a $100 resort credit, four daily cabaret show tickets and two spa passes per stay.

- Wynn and Encore Las Vegas: Up to 30% off on resort rooms, or up to 20% off on tower suites, in addition to two complimentary passes for the Buffet at Wynn.

Dining, Experiences and Attractions: Something for Everyone

- Allegiant Stadium Tours: 20% discount on select stadium tours when using promo code "LVCVA20" at checkout. The official merchandise store, The Raider Image, will also offer 20% off all online orders with code "VEGAS20."

- AREA15: Buy-one-get-one, level-one access experience passes with promo code "AREA15BOGO."

- Atomic Saloon Show at The Venetian: Up to 50% off show tickets.

- Absinthe at Caesars Palace: $20 off show tickets.

- $50 tickets to the following Caesars Entertainment shows and more on select dates:

- Josh Groban: GEMS The Las Vegas Residency

- Tim McGraw: Live In Vegas

- Thomas Rhett

- Empire Of The Sun - Ask That God: Afterlife North American Tour

- Yandel - SINFÓNICO

- Cirque du Soleil: 10% off tickets to "Michael Jackson ONE", 20% off at "O," and 30% off tickets to Mystere and KÀ.

- Dolby Live at Park MGM: Save 25% on select performances by New Kids on The Block and Mary J. Blige.

- Donny Osmond at Harrah's: Up to 30% off tickets for shows now through Saturday, June 5, 2027.

- Eiffel Tower Viewing Deck: Up to 25% off tickets.

- The LINQ Promenade: Up to 20% off High Roller Observation Wheel tickets and up to 25% off Fly LINQ Zipline tickets.

- Maverick Helicopters: 25% off popular experiences when using "citywide25" promo code.

- The Mob Museum and The Underground Speakeasy: Save 20% on general admission, deluxe and premier passes and at The Underground Speakeasy with code "WINTER26."

- The PARTY at Superfrico inside The Cosmopolitan of Las Vegas: 20% off dinner and show tickets with promo code "WIDEWINTER20."

- Papillon Helicopters: $50 off Grand Canyon package tickets with promo code "50GCW2026" and $20 off Vegas Strip package tickets with code "20LVStrip2026."

- Ru Paul's Drag Race LIVE! at Flamingo: Up to 30% off tickets.

- Speed Vegas: 10% off Speed Vegas experiences with promo code "SVWINTER26."

- Vegas Golden Knights at T-Mobile Arena: No fees on all regular-season home games.

Weddings and Romance

- Bliss Wedding Chapel: 25% off any package when booking directly.

- Chapel of the Flowers: Receive a $500+ digital wedding album for free when booking the Freemont Rooftop Wedding Experience.

- Mon Bel Ami Wedding Chapel: $50 off a Splendid Wedding Package when using code "VegasWinter."

- Vegas Weddings: $100 off the Dream Wedding Package with code "VegasDream100."

- Viva Las Vegas Wedding Chapel: $200 in upgrades on the Elvis Pink Cadillac Wedding Package. Use code "VegasPinkCaddy200" when booking.

Offers are available for a limited time and subject to availability, blackout dates and terms and conditions.

ABOUT THE LVCVA (Visit Las Vegas)

The Las Vegas Convention and Visitors Authority (LVCVA) is charged with positioning Southern Nevada as the undisputed global destination for leisure and business travel and operates the 4.6 million square-foot Las Vegas Convention Center (LVCC). With 150,000 hotel rooms and nearly 15 million square feet of meeting and exhibit space in Las Vegas, the LVCVA's mission centers on attracting visitors to the area. The LVCVA also owns the Vegas Loop at Las Vegas Convention Center, designed, and operated by The Boring Company, and also owns the Las Vegas Monorail, an elevated 3.9-mile system with seven stops throughout the resort corridor. For more information, go to www.lvcva.com, www.visitlasvegas.com or www.vegasmeansbusiness.com.

SOURCE Las Vegas Convention and Visitors Authority (LVCVA)

Share this article

Breda University: how cycling infrastructure can unlock the future of urban mobility

BREDA, Netherlands, Sept. 22, 2026 /PRNewswire/ -- New light electric vehicles (LEVs) could cut car use but they also put more cyclists at risk, according to research conducted at Breda University of Applied Sciences (BUas).

As European Mobility Week closes with Car-Free Day, the Netherlands' cycling model faces a new test.

The world's blueprint for cycling

The Netherlands built the world's reference model for cycling: 28% of all trips by bike, 22 million bicycles for 18 million residents, and a 153,000-kilometre network that is increasingly studied and copied by cities worldwide.

Lower car use

Light electric vehicles - e-scooters, e-cargo bikes and fatbikes - are arriving on Dutch cycle paths in growing numbers. Research from the LEVERAGE project of BUas and partners shows the upside: in a survey of nearly 2,000 residents, a quarter are considering a small LEV soon, and three-quarters expect to drive their car less as a result. Interest spans suburban and rural areas equally, suggesting LEVs can extend cycling-based mobility beyond conventional bikes, contributing to decarbonising the wider mobility system.

It's behaviour, not the vehicle

But LEVs also bring more varied speeds and masses to the same narrow cycle paths, and safety research finds this is pushing up cycling accidents. Using eye-tracking, skin-conductance sensors and surveys with cyclists, researchers found that legal fatbikes and other LEVs draw more visual attention than ordinary bicycles. Yet this does not translate into measurable stress or unsafety, as long as LEV users behave predictably and keep to legal speeds.

"It is not the vehicle itself that creates danger, it is how it's used," says Paul van de Coevering, professor of Urban Mobility Planning at BUas. Even participants with negative prior attitudes towards LEVs reported no unsafe experiences when encountering them riding calmly. Infrastructure matters too: separated cycle paths consistently produced higher feelings of safety.

The policy fix

Enforcing behavioural standards like age limits, speed controls and predictable riding is more effective and receives more public support than banning specific vehicles. Combined with investment in well-designed infrastructure, these measures can keep the Dutch cycling model safe as it absorbs a new generation of electric vehicles.

Note to editors

Breda University of Applied Sciences is an internationally oriented university with study programmes in Built Environment, Logistics and Hospitality.

SOURCE Breda University of Applied Sciences (BUas)

Share this article

Anyang Indorama Gases secures RMB 2.4 billion (c. US$358 million) long term financing for Fertilizer capacity expansion in Henan Province

ANYANG, China, Sept. 22, 2026 /PRNewswire/ -- Anyang Indorama Gases Co., Ltd., a wholly owned subsidiary of Indorama Corporation Pte. Ltd., Singapore ("Indorama"), has signed an RMB 2.4 billion (c. US$358 million) long-term loan facility with a consortium of five leading banks in China to finance its Phase II fertilizer capacity expansion project in Anyang City, Henan Province, China. The financing represents an important milestone in Indorama's brownfield expansion in China following its acquisition of the Anyang nitrogen fertilizer business earlier this year and reinforces the Group's commitment to building competitive, cleaner and more efficient fertilizer capacity. This expansion project is expected to double the company's urea fertilizers capacity (starting from syngas and ammonia) to c. 2 million tonnes per annum by 2029. It will further strengthen the reliability of domestic fertilizer supply contributing to increasing food security, with more energy-efficient production processes across the site.

This long-term financing was provided by OCBC Bank Limited, Bank of China Limited, Bank of Communications Co., Ltd., Bangkok Bank (China) Company Limited and China CITIC Bank Co., Ltd. OCBC Bank Limited acted as Coordinator and Facility Agent, and Sumitomo Mitsui Banking Corporation (China) Limited acted as Security Agent. This financing will be used to partially fund the development and construction of the expansion project.

Mr. Amit Lohia, Group Vice Chairman, Indorama Corporation, said: "This transaction is an important milestone in Indorama's global growth strategy and reflects the confidence of leading international and Chinese financial institutions in our business. Building on our acquisition of the Anyang business, it strengthens our fertilizer platform in one of the world's most important markets and reinforces our commitment to supporting global food security. We deeply value our banking partners' support and look forward to advancing Indorama's continued global growth."

Mr. Chai Wei Joo, Country Head (China), Indorama Corporation, said: "We deeply value the trust and partnership of our banking partners in China. This financing supports the expansion of our fertilizer capacity in Henan Province, reinforcing Indorama's role as a key industrial contributor to China's economy and national food security. It is an important step in our continued growth in China, and we look forward to investing further in the country."

Mr. Seth Tan, Managing Director & Head of Corporate Banking China, OCBC Bank Limited, said: "We are pleased to participate in and coordinate this financing alongside our partner banks in support of Indorama's investment in Henan Province. The project represents an important industrial investment that will contribute to increased fertilizer production and domestic supply. Building on our 14-year partnership with Indorama, we are pleased to further strengthen our support for the Group in China and look forward to deepening our relationship across China and Asia."

Mr. LUAN Lin, Senior Credit Approver, Bank of China Limited - Suzhou Branch, said: "We are delighted to begin our relationship in China with Indorama through this financing. As a significant investor in Henan Province, Indorama is making an important contribution to the Chinese domestic economy as well as contributing to food security, and we look forward to supporting the Group's growth in China in the years ahead."

Bank of Communications Co., Ltd. said: "This loan signing marks the beginning of our partnership with Indorama, and we are pleased to support its investment in Anyang. The project will help strengthen domestic fertilizer supply and regional industrial development, and we look forward to further deepening our cooperation with the Group."

Mr. Sitthichai Jiwattanakul, CEO, Bangkok Bank (China) Company Limited, said: "We are delighted to deepen our decade-long partnership with Indorama Group as it pursues its strategic expansion in China. This financing reflects our confidence in the Group's vision and our ongoing support for its growth both regionally and globally."

Mrs. Huang Qin, President, China CITIC Bank Co., Ltd.– Zhengzhou Branch, said: "We are pleased to establish our relationship with Indorama through this landmark financing. The project brings valuable investment and capacity to Henan Province, and we look forward to building a strong, long-term partnership with the Group."

About Indorama

Indorama Corporation, headquartered in Singapore, is a global leading producer of essential materials. It was established in 1975 in Indonesia by its founder, M.L. Lohia, and his son, S.P. Lohia with its first operations in Indonesia as a cotton yarn spinning company. Today, Indorama manufactures, through its subsidiaries, a multitude of products including nitrogen fertilizers, phosphate fertilizers, agricultural inputs, polyethylene, polypropylene, polyester, textiles, industrial chemicals, cotton fibre and medical gloves. Indorama ranks as the 5th largest global private fertilizer producer, the 4th largest producer of synthetic gloves, the largest producer of urea fertilizers in Sub-Saharan Africa and the largest producer of polyolefins in West Africa. Indorama Corporation (including through its associate companies) has a manufacturing footprint across 38 countries with over 100 sites in Asia, Europe, CIS, Africa, and North America, and a workforce of over 50,000 employees. It has aggregate revenue and assets in excess of US$20 billion and US$29 billion respectively (www.indorama.com).

SOURCE Indorama Group

Share this article

Invitation to presentation of Essity's interim report for quarter 3, 2026

STOCKHOLM, Sept. 22, 2026 /PRNewswire/ -- The hygiene and health company Essity will publish its interim report for quarter 3, 2026 on October 22 at approximately 07:00 CET. President and CEO Ulrika Kolsrud together with EVP and CFO Fredrik Rystedt will present the interim report at a live webcast and teleconference at 09:00 CET the same day.

Link to the live webcast and teleconference, which can also be viewed afterwards: 

https://essity.videosync.fi/2026-10-22 

Contact information for conference call with the possibility to ask questions:

UK: +44 (0) 33 0551 02 00 

USA: +1 786 697 35 01

SWE: +46 (0)8 505 204 24

Please call in well in advance of the start of the presentation. Indicate: "Essity". 

For additional information, please contact:

Sandra Åberg, Vice President Investor Relations, +46 70 564 96 89, [email protected]

Per Lorentz, Vice President Corporate Affairs, +46 73 313 30 55, [email protected] 

This information was brought to you by Cision http://news.cision.com.

The following files are available for download:

Share this article

Beactica Therapeutics initiates IND-enabling studies for BEA-17, a first-in-class LSD1-CoREST degrader for glioblastoma

UPPSALA, Sweden, Sept. 22, 2026 /PRNewswire/ -- Beactica Therapeutics AB, a Swedish precision medicine company, today announced the initiation of IND-enabling studies for BEA-17, the Company's wholly owned, first-in-class oral degrader of the epigenetic regulators LSD1 and CoREST, being developed as a precision immunotherapy for glioblastoma (GBM). The studies advance BEA-17 from preclinical proof-of-concept into the formal safety, manufacturing and regulatory programme required to support a Clinical Trial Application (CTA) in the EU and/or an Investigational New Drug (IND) application in the US, and the start of first-in-human clinical trials.

Glioblastoma is the most common and most aggressive primary brain tumour, with a median overall survival of around 15 months and a standard of care that has remained essentially unchanged for more than two decades. Immunotherapies that have transformed other cancers have repeatedly failed in GBM, largely because the tumour maintains a profoundly immunosuppressive, immune-"cold" microenvironment. BEA-17 is designed to overcome this barrier: by degrading LSD1 and its scaffolding partner CoREST, BEA-17 enhances antigen presentation, induces viral mimicry and reprogrammes macrophages towards a pro-inflammatory state. In preclinical models of glioblastoma, BEA-17 in combination with standard of care substantially improved survival and produced durable tumour regression not observed with standard of care alone. BEA-17 has also potentiated anti-PD-1 checkpoint blockade in a preclinical model of colon cancer – effects not seen with catalytic LSD1 inhibitors. BEA-17 is orally bioavailable, brain-penetrant, and has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of glioblastoma.

"Initiating IND-enabling studies is a defining milestone for Beactica and for the BEA-17 programme," said Dr Per Källblad, Chief Executive Officer of Beactica Therapeutics. "With a first-in-class mechanism and compelling preclinical efficacy in combination with standard of care, we are now executing the rigorous safety and manufacturing programme that will carry BEA-17 into first-in-human trials."

The IND-enabling programme comprises GLP-compliant repeat-dose toxicology in rodent and non-rodent species, safety pharmacology, pharmacokinetic studies, and manufacture of a traceable, fully documented batch of BEA-17 drug substance suitable for a Clinical Trial Application and a finalised oral clinical trial formulation.

The work is conducted under GLIOBREAK, a 30-month project supported by a EUR 2.5 million EIC Transition grant under Horizon Europe, announced in February 2026. Beactica expects to complete the IND-enabling programme and submit a Clinical Trial Application in the EU and/or an Investigational New Drug application to the US FDA in 2027.

About Beactica Therapeutics

Beactica Therapeutics AB is a privately held precision medicine company with a pipeline of novel small molecule therapeutics aimed at treating diseases with significant unmet medical need. Beactica's approach is centered around the Eclipsor™ platform that enables the efficient development of allosteric modulators and targeted protein degraders. Beactica deliver value to patients and shareholders by advancing its programmes to clinical proof of concept. For more information, please visit www.beactica.com.

Forward-looking statements

This press release contains forward-looking statements regarding Beactica's development plans for BEA-17, including the timing and outcome of IND-enabling studies and regulatory submissions. Such statements reflect current expectations, and actual results may differ materially. Beactica undertakes no obligation to update them except as required by law.

EU funding acknowledgement

Funded by the European Union under the EIC Transition programme (grant agreement No 101292011). Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Innovation Council and SMEs Executive Agency (EISMEA). Neither the European Union nor the granting authority can be held responsible for them.

Media contact

Beactica Therapeutics AB

Per Källblad M.Sc. Ph.D., CEO

[email protected]

Tel: +46 18 56 08 80

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

Share this article

PharmaResearch Officially Launches REJURAN in Hungary, Expanding Its Presence in Europe

Launch symposium at the Museum of Fine Arts, Budapest brings together around 100 aesthetic medicine professionals, with experts from Korea, the Czech Republic, Slovakia and Hungary sharing clinical experience

SEOUL, South Korea, Sept. 22, 2026 /PRNewswire/ -- PharmaResearch, the Korean pharmaceutical company behind the globally recognized skin booster REJURAN, officially launched its portfolio of PN (polynucleotide)-based REJURAN products in Hungary at a symposium in Budapest on September 14, marking another step in the company's continued expansion across Europe.

Held at the Museum of Fine Arts, Budapest—one of Hungary's leading national art institutions—the symposium marked REJURAN's first collaboration with the museum and brought together approximately 100 dermatologists, plastic surgeons, and other aesthetic medicine professionals. The setting provided a distinctive platform for REJURAN to present its clinical experience, treatment philosophy and scientific approach to the local medical community while reinforcing the brand's premium positioning.

The program featured seven speakers from Korea, the Czech Republic, Slovakia, and Hungary, including Korean REJURAN key opinion leaders Dr. Hyun Jun Park and Dr. Kyu Ho Lee. Across a series of scientific sessions, the faculty discussed the role of PN in skin regeneration, clinical applications of REJURAN and treatment approaches informed by their respective clinical experience.

The Korean faculty also presented the different applications within the REJURAN portfolio: REJURAN, designed for broader facial treatment; REJURAN I, developed for delicate areas such as the periorbital region; and REJURAN S, intended for targeted treatment of wrinkles and scars.

Live demonstrations complemented the scientific sessions, giving attendees an opportunity to observe REJURAN treatment protocols and review practical considerations for use in clinical practice.

Interest in skin quality-focused treatments continues to grow within Hungary's aesthetic medicine market alongside established injectable treatments such as botulinum toxin and hyaluronic acid fillers. As patients become increasingly informed about aesthetic procedures, demand has been shifting toward natural-looking results and treatments with limited downtime. Physicians are also showing growing interest in multimodal protocols that combine injectables with energy-based devices and other aesthetic treatments.

Following the launch, PharmaResearch will begin expanding distribution of the three REJURAN products in Hungary in partnership with its local distributor. The company plans to broaden its network of REJURAN clinics and physicians across major cities while supporting clinical adoption through product education and hands-on training.

"This launch represents more than the introduction of REJURAN to a new market," said a PharmaResearch spokesperson. "It gave us the opportunity to share the clinical experience and treatment expertise developed in Korea while engaging directly with physicians in Hungary. We will continue investing in physician education and scientific exchange as we establish REJURAN in Hungary and expand into additional European markets."

About PharmaResearch

PharmaResearch is a pioneering South Korean biopharmaceutical company dedicated to enhancing quality of life through regenerative medicine. Its portfolio spans medicines, medical devices, cosmetics and health supplements, built around its core DOT™ PDRN and DOT™ PN technologies, which are protected by multiple patents. PharmaResearch is headquartered in Gangneung, South Korea.

The company is behind REJURAN, its globally recognized PN-based skin booster available in more than 50 countries, and REJURAN COSMETICS, its premium derma-cosmetic brand.

Share this article

accesso® Intelligence Introduces Agentic AI for Automated Workflows in Visitor Attractions

New capabilities help teams automate analysis, forecasting, reporting and work across their operations

LONDON, Sept. 22, 2026 /PRNewswire/ -- accesso Technology Group (AIM: ACSO), a leading global technology provider for the leisure, entertainment and cultural markets, today introduced new capabilities that enable attraction operators to turn conversations with accesso Intelligence into recurring automated workflows. Users can now ask the platform to monitor performance, conduct research, detect and investigate changes, develop forecasts, produce reports and share findings with designated stakeholders.

Visitor attractions are complex organisations that operate multiple businesses under one roof, with data spread across ticketing, memberships, food and beverage, retail, parking, operations and other systems. accesso Intelligence, a decision intelligence platform purpose-built for visitor attractions, combines this valuable information together with relevant operational and external context. The result is a fully assembled platform that gives teams a more complete view of their business without requiring them to juggle multiple data and AI tools that don't integrate.

Through conversation, teams can define the analytical work required, select the appropriate tools and connected data, interpret the results and put the resulting workflow to work across the operation.

"What began as a conversation with your operation is becoming a new way of working within it," said Angie Judge, Chief Data and Intelligence Officer at accesso. "This is more than just a new way to analyse data. Teams can now delegate ongoing analytical work to accesso Intelligence, allowing people to focus their time on the decisions, creativity and accountability that require human judgement."

The expansion introduces three new connected capabilities:

- Agentic skills: accesso Intelligence can select and use specialised capabilities to perform multi-step analytical work, such as monitoring performance, detecting and evaluating changes and communicating issues that require attention.

- Agentic automations: Work created and refined through conversation can be scheduled or triggered repeatedly and conditionally. This can include conducting analyses, updating information and distributing results.

- Agentic reporting and forecasting: Teams can build and operationalise custom reports. The platform can determine the best predictive approach for each task, combining relevant operational context and external signals. Reports can adapt to what the data shows, rather than saying the same thing every day.

Traditional automation follows predefined steps. Agentic automation begins with an objective. accesso Intelligence determines the work required, selects the appropriate tools and connected data, interprets the results and delivers the requested outcome.

For example, an operator could ask accesso Intelligence to compare weekly visitation and revenue against plan, investigate any meaningful variance and consider relevant operational and external factors. The platform could then assess whether reforecasting is required.

From that conversation, the platform can create a repeatable workflow that monitors results, examines important changes and delivers recommendations and reasoning to the people who need them.

"The next stage of AI in attractions is not simply helping people find an answer," Judge said. "It is helping teams continuously monitor their business, recognise when conditions change and bring the right recommendation to the right person at the right time." accesso Intelligence brings data integration, industry-specific semantic modelling, machine learning, visualisation, reporting, conversational insight and workflow automation together in one platform.

The capabilities are available now within accesso Intelligence.

Attendees at IAAPA Expo Europe can learn more about accesso Intelligence and the broader accesso ecosystem at Booth S2123, 22–24 September at ExCeL London. Booth visitors can also request a complimentary personalised visitor-experience report identifying where decision intelligence could help reveal opportunities within their venue.

About accesso Intelligence

accesso Intelligence connects data across the systems that run an attraction and applies AI built on a decade of visitor attractions-specific expertise. The result is a decision intelligence platform that helps teams make faster, smarter and more confident decisions without having to build the underlying infrastructure themselves.

About accesso Technology Group plc

The accesso ecosystem of solutions redefines the guest experience. accesso offers the agility of connected ticketing and eCommerce, virtual queuing, restaurant and retail point of sale, distribution, mobile apps and decision intelligence and analytics solutions for more than 1,100 venues globally. Its technology helps operators streamline operations, increase revenue and improve the guest journey. accesso delivers a high volume of product enhancements year-round and continuously invests in R&D to help venues and operators adapt to evolving guest needs.

accesso is a public company, listed on AIM: a market operated by the London Stock Exchange. Learn more at accesso.com or follow accesso on X (Twitter), LinkedIn and Facebook.

SOURCE accesso Technology Group

Share this article